Alliant Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alliant Pharmaceuticals, Inc.
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.
Daewoong Innovation Holdings President Thierry Uh tells Scrip what Korean pharma firms should keep in mind when entering the US market, as well as what R&D and partnering strategies Daewoong has both there and globally.
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
- Medical Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.